^
    3d
    A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants. (clinicaltrials.gov)
    P1, N=16, Completed, Novartis Pharmaceuticals | Recruiting --> Completed
    Trial completion
    |
    Rhapsido (remibrutinib)
    7d
    Properties of FDA-approved small molecule protein kinase inhibitors: a 2026 update. (PubMed, Pharmacol Res)
    The following ten drugs received FDA approval in 2025 - avutometinib (inhibiting MEK1/2 in serous ovarian carcinomas), defactinib (blocking FAK in low grade serous ovarian carcinomas), delgocitinib (antagonizing the JAK family in hand eczema), mirdametinib (inhibiting MEK1/2 in type I neurofibromatosis), remibrutinib (blocking BTK in chronic spontaneous urticaria), rilzabrutinib (antagonizing BTK in chronic immune thrombocytopenia), sunvozertinib (blocking mutant exon 21 insertion EGFR NSCLC), taletrectinib (inhibiting mutant ROS1 in NSCLC), vimseltinib (blocking CSF1R in tenosynovial giant cell tumors), and zongertinib (antagonizing mutant HER2 in NSCLC). This article summarizes the physicochemical properties of all 94 FDA-approved small molecule protein kinase inhibitors including the molecular weight, number of hydrogen bond donors/acceptors, ligand efficiency, lipophilic efficiency, polar surface area, and solubility. A total of 45 of the 94 FDA-approved drugs have a least one Lipinski rule of five violation.
    FDA event • Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CSF1R (Colony stimulating factor 1 receptor)
    |
    EGFR mutation
    |
    Gomekli (mirdametinib) • Avmapki (avutometinib) • Hernexeos (zongertinib) • Fakzynja (defactinib) • Ibtrozi (taletrectinib) • Zegfrovy (sunvozertinib) • Rhapsido (remibrutinib) • Romvimza (vimseltinib)
    11d
    REASSERT: Remibrutinib in Real-world Clinical Practice - a US Sub-study (clinicaltrials.gov)
    P=N/A, N=505, Not yet recruiting, Novartis Pharmaceuticals
    New trial • Real-world evidence
    |
    Rhapsido (remibrutinib)
    11d
    REASSERT: Remibrutinib in Real-world Clinical Practice (clinicaltrials.gov)
    P=N/A, N=3280, Not yet recruiting, Novartis Pharmaceuticals
    New trial • Real-world evidence
    |
    Rhapsido (remibrutinib)
    12d
    RECHARGE 2: A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov)
    P3, N=555, Recruiting, Novartis Pharmaceuticals | Trial completion date: Oct 2028 --> Mar 2028 | Trial primary completion date: Jun 2028 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Rhapsido (remibrutinib)
    12d
    A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) (clinicaltrials.gov)
    P3, N=555, Recruiting, Novartis Pharmaceuticals | Trial completion date: Oct 2028 --> Feb 2028 | Trial primary completion date: Sep 2028 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Rhapsido (remibrutinib)
    2ms
    REMASTER: A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis (clinicaltrials.gov)
    P3, N=1275, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rhapsido (remibrutinib)
    3ms
    REMASTER: A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis (clinicaltrials.gov)
    P3, N=1275, Not yet recruiting, Novartis Pharmaceuticals
    New P3 trial
    |
    Rhapsido (remibrutinib)
    3ms
    A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines (clinicaltrials.gov)
    P3, N=364, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Dec 2028 --> Aug 2028
    Enrollment closed • Trial completion date • Pan tumor
    |
    Rhapsido (remibrutinib)
    5ms
    A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants. (clinicaltrials.gov)
    P1, N=16, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rhapsido (remibrutinib)
    6ms
    Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. (clinicaltrials.gov)
    P3, N=360, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open • Head-to-Head
    |
    Rhapsido (remibrutinib) • Ocrevus (ocrelizumab)
    7ms
    RECLAIM: A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines (clinicaltrials.gov)
    P3, N=400, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rhapsido (remibrutinib) • Dupixent (dupilumab)